Chemotherapy induced nausea & vomiting (CINV)

Bannur R. Nandeesh, T. M. Reddy

Abstract


Chemotherapy is the first line treatment in management of many cancers, both for cure and palliation; hence it’s crucial to minimize the unpleasant side effects of chemotherapy to increase tolerability to chemotherapy. Most of the conventional anti cancer drugs are emetogenic. Patients receiving chemotherapy experience different degrees of nausea and vomiting depending on the emetogenic potential of the anti cancer drugs given and the patient characteristics. With a better understanding of the pathophysiology, distinct phases of chemotherapy-induced nausea and vomiting (CINV) i.e., acute emesis, delayed emesis and anticipatory emesis have been identified. Identification of various mediators has led to the development of different drugs acting through different mechanisms which are useful in the prevention and treatment of CINV. Serotonin receptor three (5-HT3) antagonists, corticosteroids and neurokinin type one receptor (NK-1) antagonists are of proven usefulness and have wide therapeutic indexes in the prevention of CINV. Other drugs like dopamine receptor antagonists & benzodiazepines are not routinely used because of their narrow therapeutic index. Practice guidelines for prevention of CINV will not only improve patient’s tolerability to chemotherapy & wellbeing, but also decrease hospital stay and overall cost of treatment of the patient.


Keywords


Chemotherapy Induced Nausea and Vomiting (CINV), 5-HT3 receptor antagonist, Neurokinin type one receptor antagonist, Corticosteroids

Full Text:

PDF

References


Herrstedt J. Nausea and emesis: Still an unsolved problem in cancer patients? Support Care Cancer 2002;10:85-7.

Miller M, Kearney N. Chemotherapy-related nausea and vomit¬ing – past reflections, present practice and future management. Eur J Cancer Care 2004;13:71-81.

Pollera CF, Giannarelli D. Prognostic factors influencing cisplatin-induced emesis. Definition and validation of a predictive logistic model. Cancer 1989;64:1117-22.

Osoba D, Zee B, Pater J, Warr D, Latrielle J, Kaizer L. Determinants of post chemotherapy nausea and vomiting in patients with cancer. Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1997;15:116-23.

Roila F, Hesketh PJ, Herrstedt J et al. Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer. Prevention of chemotherapy- and radiotherapy-induced emesis: Results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 2006;17:20-8.

Grunberg SM, Osoba D, Hesketh PJ et al. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity- an update. Support Care Cancer 2005;13:80-4.

Jordan K, Grothey A, Kegel T et al. Antiemetic efficacy of an oral suspension of granisetron plus dexamethasone and influence of quality of life on risk for nausea and vomiting. Onkologie 2005;28:88-92.

Schnell FM. Chemotherapy-induced nausea and vomiting: the importance of acute anti emetic control. Oncologist 2003;8:187-98.

Hesketh PJ, Kris MG, Grunberg SM et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 1997;15:103-9.

Andrews PL, Davis CJ, Bingham S, Davidson HI, Hawthorn J, Maskell L. The abdominal visceral innervation and the emetic reflex: pathways, pharmacology, and plasticity. Can J Physiol Pharmacol 1990;68:325-45.

Roila F, Donati D, Tamberi S, Margutti G. Delayed emesis: incidence, pattern, prognostic factors and optimal treatment. Support Care Cancer 2002;10:88-95.

Roila F, Donati D, Tamberi S et al. Delayed emesis: Incidence, pattern, prognostic factors and optimal treatment. Support Care Cancer 2002;10:88-95.

Alvarez O, Freeman A, Bedros A, et al. Randomized double-blind crossover ondansetron-dexamethasone versus ondansetron-placebo study for the treatment of chemotherapy-induced nausea and vomiting in pediatric patients with malignancies. J Pediatr Hematol Oncol 1995;17:145-50.

Hirota T, Honjo T, Kuroda R, et al. Antiemetic efficacy of granisetron in pediatric cancer treatment. Comparison of granisetron and granisetron plus methylprednisolone as antiemetic prophylaxis. Jpn J Clin Oncol 1993;20:2369-73.

Rubenstein EB, Gralla RJ, Eisenberg P et al. Palonosetron (PALO) compared with ondansetron (OND) or dolasetron (DOL) for prevention of acute and delayed CINV: Combined results of two phase III trials. Proc Am Soc Clin Oncol 2003,22:729.

Hesketh P, Navari R, Grote T, et al. Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. J Clin Oncol 1996;14:2242-9.

Audhuy B, Cappelaere P, Martin M, et al. A double-blind, randomised comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy. Eur J Cancer 1996;32A:807-13.

Hutt AJ, Tan SC. Drug chirality and its clinical significance. Drugs 1996; 52 Suppl 5:1-12.

Eisenberg P, Figueroa-Vadillo J, Zamora R, Charu V, Hajdenberg J, Cartmell A et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist results of a phase III, single-dose trial versus dolasetron. Cancer 2003;98:2473-82.

Kris MG. Why do we need another antiemetic? Just ask. J Clin Oncol 2003;21:4077-80.

Diemunsch P, Grelot L. Potential of substance P antagonists as antiemetics. Drugs 2000;60:533-46.

Warr DG, Hesketh PJ, Gralla RJ et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 2005;23:2822-30.

Hesketh PJ, Grunberg SM, Gralla RJ et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin-the Aprepitant Protocol 052 Study Group. J Clin Oncol 2003;21:4112-9.

Poli-Bigelli S, Rodrigues-Pereira J, Carides AD et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 2003;97:3090-8.

De Wit R, Herrstedt J, Rapoport BL et al. Addition of the oral NK1 antagonist aprepitant to standard antiemetics provided protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. J Clin Oncol 2003;21:4105-11.

Herrstedt J, Muss HB, Warr DG et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy. Cancer 2005;104:1548-55.

De Witt R, Herrstedt J, Rapoport B et al. The oral NK1 antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III trials. Eur J Cancer 2004;40:403-10.

Navari R, Reinhardt R, Gralla RJ et al. Reduction of cisplatin- induced emesis by a selective neurokinin-1 receptor antagonist. N Engl J Med 1999;340:190-5.

Van Belle S, Lichinitser MR, Navari R et al. Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869: a randomized controlled trial. Cancer 2002;94:3032-41.

Campos D, Pereira JR, Reinhardt RR et al. Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J Clin Oncol 2001;19:1759-67.

Navari R, Reinhardt R, Gralla RJ et al. Reduction of cisplatin-induced emesis by a selective neurokinin-1 receptor antagonist. N Engl J Med 1999;340:190-5.

Majumdar AK, Howard L, Gold berg MR, Hickey L, Constanzer M, Rothenberg PL et al. Pharmacokinetics of aprepitant after single and multiple oral doses in healthy volunteers. J Clin Pharmacol 2006;46:291-300.

McCrea JB, Majumdar AK, Goldberg MR et al. Effects of the neurokinin 1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone. Clin Pharmacol Ther 2003;74:17-24.

Majumdar AK, McCrea JB, Panebianco DL, Hesney M, Dru J, Constanzer M, et al. Effects of apretitant on cytochrome P4503A4 activity using midazolam as a probe. Cli Pharmacol Ther 2003;74:150-6.

Viale PH. Update on the management of chemotherapy-induced nausea and vomiting. J Infus Nurs 2006;29:283-92.

Massaro AM, Lenz KL. Apetitant: A novel antiemetic for chemotherapy-induced nausea and vomiting. Ann Pharmacother 2005;39:77-85.

Bergman AJ, Marbury T, Fosbinder T, Swan S, Hickey L, Bradstreet TE et al. Effect of impaired renal function and haemodialysis on the pharmaco kinetics of aprepitant. Clin Pharmacokinet 2005;44:637-47.

Chawla SP, Grunberg SM, Gralla RJ et al. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Cancer 2003;97:2290-300.

Grote T, Hajdenberg J, Cartmell A et al. Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant. J Support Oncol 2006;4:403-8.

Alvarez O, Freeman A, Bedros A et al. Randomized double-blind crossover ondansetron-dexamethasone versus ondansetron-placebo study for the treatment of chemotherapy-induced nausea and vomiting in pediatric patients with malignancies. J Pediatr Hematol Oncol 1995;17:145-50.

Hajdenberg J, Grote T, Yee L et al. Infusion of Palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting. J Support Oncol 2006;4:467-71.

Young SN. Mechanism of decline in rat brain 5-hydroxytryptamine after induction of liver tryptophan pyrrolase by hydrocortisone: roles of tryptophane catabolism and kynurenine synthesis. Br J Pharmacol 1981;74:695-700.

Harris AL. Cytotoxic-therapy-induced vomiting is mediated via enkephalin pathways. Lancet 1982;1:714-6.

Warr DG, Hesketh PJ, Gralla RJ et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 2005;23:2822-30.

Del Priore G, Gurski K, Warshal D. Adrenal function following high-dose steroids in ovarian cancer patients. Gynecol Oncol 1995;59:102-4.

Moertel CG, Reitemeier RJ, Gage RP. A controlled clinical evaluation of antiemetic drugs. JAMA 1963;186:116-8.

Saller R, Hellenbrecht D. High doses of metoclopramide or droperidol in the prevention of cisplatin-induced emesis. Eur J Cancer Clin Oncol 1986;22:1199-203.

Blower PR. The role of specific 5-HT3 receptor antagonism in the control of cytostatic drug-induced emesis. Eur J Cancer 1990;26 Suppl 1:S8-11.

Navari RM, Einhorn LH, Loehrer PJ Sr, Passik SD, Vinson J McClean J et al. A Phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study. Support Care Cancer 2007;15:1285-91.

Tsavaris N, Tsoutsos H, Bacoyannis C, Mylonakis N, Karvounis N, Kozatsani-Halividi D et al. Antiemetic efficacy of alprazolam in carboplatin-induced emesis. Chemotherapy 1991;37:364-70.

Razavi D, Delvaux N, Farvacques C, De Brier F, Van Heer C, Kaufman L et al. Prevention of adjustment disorders and anticipatory nausea secondary to adjuvant chemotherapy: a double-blind, placebo-controlled study assessing the usefulness of alprazolam. J Clin Oncol 1993;11:1384-90.

Ekert H, Waters KD, Jurk IH et al. Amelioration of cancer chemotherapy induced nausea and vomiting by delta-9-tetrahydrocannabinol. Med J Aust 1979;2:657-9.

Chan HS, Correia JA, MacLeod SM. Nabilone versus prochlorperazine for control of cancer chemotherapy-induced emesis in children: a double-blind, crossover trial. Pediatrics 1987;79:946-52.

Grinspoon L, Bakalar JB. Marihuana as medicine: a plea for reconsideration. JAMA 1995;273:1875-6.

Kassirer JP. Federal foolishness and marijuana. N Engl J Med 1997;336:366-7.

Tramèr MR, Carroll D, Campbell FA, Reynolds DJ, Moore RA, McQuay HJ. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantita¬tive systematic review. BMJ 2001;323:16-21.

Davis M, Maida V, Daeninck P, Pergolizzi J. The emerging role of cannabinoid neuromodulators in symptom management. Support Care Cancer 2007;15:63-71.

Chang AE, Shiling DJ, Stillman RC, Goldberg NH, Seipp CA, Barofsky I. Delata-9-tetrahydrocannabinol as an antiemetic in cancer patients receiving high-dose methotrexate. A prospective, randomized evaluation. Ann Intern Med 1979;91:819-24.

Lee JW, Bromfield EB. Kesari S. Antiemetic properties of the antiepileptic drug levetiracetam NEJM 2008;359:1853.

Kris MG, Hesketh PJ, Somerfeild MR et al. American society of clinical oncology guideline for antiemetics in oncology: update 2006; J Clin Oncol 2006;24:2932-47.